CD19 and non-Hodgkin lymphoma: Since bispecific antibodies including blinatumumab, which brings a cytotoxic T cell and the cancer target cell in close proximity and effectively eradicates tumor cells, has been investigated and indicated high response rates in cases with both NHL and ALL, it is considered as promising B-lineage anti-tumoral drug tested in various clinical trials for NHL and ALL and is the first anti-CD19 approved drug for precursor B-cell ALL in December 2014.